CD99 and neoplasm: Here we report the absolutely preliminary results of a clinical study in which we evaluated the expression of β3-ARs on EWS tumour and microenvironmental cells and hypothesize that the investigation of its levels on CD99+ cells could be used as a marker of disease recurrence during the follow-up of patients independently from the number of circulating CD99+ cells.